KRP vs SRPT · P/E 33, rev $178.0M vs rev $1.13B
Kimbell Royalty Partners LP (KRP) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Kimbell Royalty Partners LP (KRP) is a oil & gas e&p company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported KRP revenue for 2026-06-30 was $178.0M. Net income was $54.2M. KRP currently screens at market cap $1.64B and trailing P/E 33.1.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
KRP currently screens at market cap $1.64B and trailing P/E 33.1. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the KRP and SRPT stock pages for the full models.
Not investment advice.